ArticleFrontiers in medicine2026
JinHuangJieDu (JHJD) formula attenuates SARS-CoV-2 infection by interrupting RBD-ACE2 binding and HIF-1α-dependent inflammation.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Since the emergence and spread of coronavirus disease 2019 (COVID-19), Traditional Chinese Medicine (TCM) and its formulations have been used extensively in China for preventing and treating COVID-19 with demonstrated clinical efficacy. This study aimed to evaluate both the therapeutic potential and the mechanism of action of a newly designed TCM formula, JinHuangJieDu (JHJD), which is composed of Methods: The inhibitory effects of JHJD on SARS-CoV-2 spike RBD binding to ACE2 and pseudovirus infection were assessed Results: JHJD effectively blocked wildtype and Omicron RBD binding to ACE2 and inhibited pseudovirus infection. Network analyses identified 375 ingredients, 338 targets (primarily in lung, stomach and spleen), and 63 significant pathways related to viral infection/inflammation. Intersectional analysis suggested Conclusion: JHJD, a de novo designed TCM formula, effectively inhibits SARS-CoV-2 entry with superior efficacy against Omicron sub-variants. The formulation has a dual mode of action including disruption of the RBD-ACE2 interaction and alleviation of virus-induced inflammation by modulating HIF-1α. These dual mechanisms establish JHJD as a promising therapeutic candidate for COVID-19.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.